Evidence map›Paper›PMID 40083772›Full record

ArticleMedicine international

Evaluation of the association between serum danger molecules at diagnosis and survival outcomes in patients with diffuse large B cell lymphoma.

Rafiye Çiftçiler, Ali Erdinc Ciftciler, Cem Selim

Abstract read
In one paragraph

Article in Medicine international. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rafiye ÇiftçilerDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Selçuk University, 42131 Konya, Turkey.
Ali Erdinc CiftcilerDepartment of General Surgery, Konya Numune Hospital, 42060 Konya, Turkey.
Cem SelimDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Selçuk University, 42131 Konya, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

When cellular stress or tissue injury occurs, molecules known as damage-associated molecular patterns are generated. The aim of the present was to examine the association between serum danger molecules and survival outcomes in patients with diffuse large B cell lymphoma (DLBCL) at the time of diagnosis. The present study was carried out retrospectively. An evaluation was conducted on 122 patients with DLBCL who were diagnosed at a tertiary care center between 2011 and 2024. The laboratory results of the patients diagnosed with DLBCL, which were examined in detail at diagnosis, were examined retrospectively. The median age of the patients was 59 years (range, 22-87 years) and 56.6% (n=69) of the patients were female. The 5-year overall survival (OS) rates of the patients who had a fibrinogen level ≤424 mg/dl and of those who had a fibrinogen level >424 mg/dl at the time of diagnosis were 82 and 41%, respectively (P<0.001). The 5-year progression-free survival (PFS) rates of the patients with a fibrinogen level ≤424 mg/dl and of those with a fibrinogen level >424 mg/dl at the time of diagnosis were 91 and 63%, respectively (P=0.002). The 5-year OS rates of patients with a uric acid level ≤5 mg/dl and those with a uric acid level >5 mg/dl at the time of diagnosis were 74 and 44%, respectively (P=0.008). The 5-year PFS rates of patients with a uric acid level ≤5 mg/dl and those with a uric acid level >5 mg/dl at the time of diagnosis were 83 and 71%, respectively (P=0.95). On the whole, the present study demonstrates that high uric acid and fibrinogen levels are negative prognostic factors for the OS and PFS of patients with DLBCL. These data may indicate that uric acid and fibrinogen levels at the time of diagnosis may provide predictive information to the existing library of clinical risk prediction tools in DLBCL.

Indexed as

damage-associated molecular patternsdiffuse large B cell lymphomafibrinogenuric acid

Identifiers

PMID40083772
PMCPMC11904874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.